These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33542480)

  • 1. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.
    Baumann T; Moia R; Gaidano G; Delgado J; Condoluci A; Villamor N; Payedimarri AB; Costa D; Patriarca A; Jiménez-Vicente C; Rossi D; Montserrat E
    Leukemia; 2021 Aug; 35(8):2325-2331. PubMed ID: 33542480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of four prognostic scoring system in patients with early asymptomatic chronic lymphocytic leukemia patients].
    Sha YQ; Shen H; Wu W; Xia Y; Miao Y; Cao L; Wang L; Fan L; Xu W; Li JY; Zhu HY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):834-839. PubMed ID: 34788923
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group.
    Hoechstetter MA; Busch R; Eichhorst B; Bühler A; Winkler D; Bahlo J; Robrecht S; Eckart MJ; Vehling-Kaiser U; Jacobs G; Jäger U; Hurtz HJ; Hopfinger G; Hartmann F; Fuss H; Abenhardt W; Blau I; Freier W; Müller L; Goebeler M; Wendtner C; Fischer K; Herling CD; Starck M; Bentz M; Emmerich B; Döhner H; Stilgenbauer S; Hallek M
    Leukemia; 2020 Apr; 34(4):1038-1051. PubMed ID: 32042081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia.
    Morabito F; Tripepi G; Moia R; Recchia AG; Boggione P; Mauro FR; Bossio S; D'Arrigo G; Martino EA; Vigna E; Storino F; Fronza G; Di Raimondo F; Rossi D; Condoluci A; Colombo M; Fais F; Fabris S; Foa R; Cutrona G; Gentile M; Montserrat E; Gaidano G; Ferrarini M; Neri A
    Front Oncol; 2021; 11():684621. PubMed ID: 34408978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
    Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
    Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
    International CLL-IPI working group
    Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
    Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
    Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
    Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
    Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S
    Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.
    Langerbeins P; Giza A; Robrecht S; Cramer P; von Tresckow J; Al-Sawaf O; Fink AM; Fürstenau M; Kutsch N; Simon F; Goede V; Hoechstetter M; Niemann CU; da Cunha-Bang C; Kater A; Dubois J; Gregor M; Staber PB; Tausch E; Schneider C; Stilgenbauer S; Eichhorst B; Fischer K; Hallek M
    Blood; 2024 Jun; 143(25):2588-2598. PubMed ID: 38620092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
    Hallek M
    Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.
    Bulian P; Rossi D; Forconi F; Del Poeta G; Bertoni F; Zucca E; Montillo M; Pozzato G; D'Arena G; Efremov DG; Marasca R; Lauria F; Gaidano G; Gattei V; Laurenti L
    J Transl Med; 2012 Jan; 10():18. PubMed ID: 22289136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic significance of CLL-IPI for Chinese patients with chronic lymphocytic leukemia].
    Zhu HY; Wang L; Qiao J; Zou YX; Xia Y; Wu W; Cao L; Liang JH; Fan L; Xu W; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):392-397. PubMed ID: 29779348
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.
    Mato A; Nabhan C; Kay NE; Lamanna N; Kipps TJ; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Kiselev P; Swern AS; Bhushan S; Sullivan K; Flick ED; Sharman JP
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):114-124.e2. PubMed ID: 29352719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.
    Molica S; Shanafelt TD; Giannarelli D; Gentile M; Mirabelli R; Cutrona G; Levato L; Di Renzo N; Di Raimondo F; Musolino C; Angrilli F; Famà A; Recchia AG; Chaffee KG; Neri A; Kay NE; Ferrarini M; Morabito F
    Am J Hematol; 2016 Nov; 91(11):1090-1095. PubMed ID: 27465919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia.
    Leslie LA; Gangan N; Tan H; Huang Q
    Curr Med Res Opin; 2022 Dec; 38(12):2149-2161. PubMed ID: 36205521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.